Specify a stock or a cryptocurrency in the search bar to get a summary
Pharmaron Beijing Co Ltd
3759Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China. Address: Building 1, Beijing, China, 100176
Analytics
WallStreet Target Price
132.9 HKDP/E ratio
13.8783Dividend Yield
1.57 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 3759
Dividend Analytics 3759
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
23 %Dividend History 3759
Stock Valuation 3759
Financials 3759
Results | 2019 | Dynamics |